- Home
- PHAT vs HPP Comparison
PHAT vs HPP Comparison
Compare PHAT & HPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAT | HPP |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 590.6M | 535.6M |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | PHAT | HPP |
|---|---|---|
| Price | $5.22 | $8.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 12 |
| Target Price | ★ $20.05 | $16.27 |
| AVG Volume (30 Days) | ★ 1.8M | 838.8K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.72 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $175,110,000.00 | ★ $831,105,000.00 |
| Revenue This Year | $79.63 | N/A |
| Revenue Next Year | $54.71 | $4.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $5.02 | $1.67 |
| 52 Week High | $18.31 | $17.20 |
Technical Indicators
Market Signals| Indicator | PHAT | HPP |
|---|---|---|
| Relative Strength Index (RSI) | 30.97 | 31.97 |
| Support Level | $5.02 | $5.38 |
| Resistance Level | $11.85 | $12.24 |
| Average True Range (ATR) | 0.62 | 0.79 |
| MACD | -0.08 | -0.16 |
| Stochastic Oscillator | 7.10 | 3.19 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About HPP Hudson Pacific Properties Inc.
Hudson Pacific Properties Inc is a vertically integrated real estate investment trust offering end-to-end real estate solutions for dynamic tenants in the synergistic, converging and secular growth industries of tech and media. It acquires, repositions, develops and operates sustainable high-quality office studio properties in high-barrier-to-entry tech and media epicenters. Its primary investment markets include Los Angeles, the San Francisco Bay Area, Seattle, New York and Vancouver, British Columbia. Its segments include Office properties and related operations and Studio properties and related operations. The majority of the revenue is derived from Office properties and related operations segment.